Aplastic Anemia Treatment by Dr Rahul Bhargava

Aplastic anemia is a rare but serious blood disorder in which the bone marrow fails to produce enough red blood cells, white blood cells, and platelets. This condition leads to chronic fatigue, frequent infections, and an increased risk of bleeding. Aplastic anemia can be either acquired, resulting from autoimmune reactions, diseases, or certain medications, or inherited, as seen in conditions such as Fanconi anemia. The cost of immunosuppressive therapy in India typically ranges from $8,000 to $12,000 USD. In comparison, a bone marrow transplant may cost around $25,000 to $35,000 USD, compared to $250,000 or more in countries like the USA. Supportive care, including blood transfusions and post-treatment monitoring, can add $1,500 to $3,000 USD annually, making India a top destination for cost-effective, world-class treatment for aplastic anemia.

What Is Aplastic Anemia?

Aplastic anemia is a rare but serious blood disorder in which the bone marrow fails to produce enough new blood cells. Bone marrow is the soft, spongy tissue inside bones that makes red blood cells, white blood cells, and platelets. In aplastic anemia, this production slows down or stops altogether, leading to a condition called pancytopenia — a shortage of all three types of blood cells.

How many types of Aplastic Anemia?

1. Acquired Aplastic Anemia (Most Common)

This type develops later in life and is not inherited. It occurs when something damages the bone marrow, resulting in reduced or stopped production of blood cells. Common Causes:

• Autoimmune response (the body attacks its marrow)
• Viral infections (e.g., Hepatitis, EBV, HIV)
• Medications (e.g., chemotherapy, antibiotics like chloramphenicol)
• Toxins and chemicals (e.g., benzene, pesticides)
• Radiation or cancer therapy
• Unknown (Idiopathic) – No clear cause in ~70% of cases

Age group: Most commonly affects adolescents and adults Treatments: Immunosuppressive therapy or bone marrow transplant

2. Inherited (Congenital) Aplastic Anemia

This type is caused by genetic mutations passed from parents to children. It is usually diagnosed in early childhood and may be associated with physical abnormalities or other syndromes. Major Subtypes:

• Fanconi Anemia (FA) – Most common inherited type
  • Associated with bone malformations, short stature, and skin pigmentation
• Dyskeratosis Congenita
  • Affects nails, skin, and causes marrow failure
• Shwachman-Diamond Syndrome
• Diamond-Blackfan Anemia (rare, often classified separately)

Age group: Infants and young children Treatments: Bone marrow transplant is often required early in life

Summary Table

Symptoms of Aplastic Anemia:

Common Symptoms:

• Extreme Fatigue and Weakness: Due to a lack of red blood cells.
• Shortness of Breath: Often related to anemia.
• Frequent or Prolonged Infections: Due to a deficiency of white blood cells.
• Easy Bruising or Bleeding: Because of a low platelet count.
• Skin Rashes: Often related to low platelet counts.
• Dizziness or Lightheadedness: Resulting from anemia.

How Is It Diagnosed?

Diagnostic Workup Includes:

• Complete Blood Count (CBC): Shows pancytopenia
• Reticulocyte count: Low
• Bone Marrow Biopsy: Hypocellular marrow with no infiltration or fibrosis
• Serologic tests: Rule out viral causes (EBV, Hepatitis, HIV)
• Flow cytometry: To rule out PNH (Paroxysmal Nocturnal Hemoglobinuria)
• Genetic tests: If inherited causes are suspected

Severity Classification

First-Line Treatments

A. Allogeneic Bone Marrow Transplant (BMT)

• Indication: Preferred for patients <40 years with a matched sibling donor
• Conditioning regimen: Cyclophosphamide + ATG ± Fludarabine
• Outcome: 75–90% survival with sibling donor transplant

Cost in India for international patients: $25,000 – $35,000

B. Immunosuppressive Therapy (IST)

• Indicated for:
  • Patients >40 years
  • No matched sibling donor
  • Moderate to severe disease
• Standard Protocol (Horse ATG + Cyclosporine):
  • ATG (Antithymocyte Globulin): 40 mg/kg/day × 4 days
  • Cyclosporine: 5 mg/kg/day (oral), continued for 6–12 months
  • ± Eltrombopag (TPO receptor agonist) to improve outcomes
• Response Rate: ~60–70% within 3–6 months

Cost in India (IST full course): $8,000 – $12,000

Supportive Management

• Blood transfusions: PRBCs and platelets as needed
• Infection control: Prophylactic antibiotics/antifungals
• Growth factors: G-CSF may be used selectively
• Iron chelation therapy: For transfusion-related iron overload

Second-Line and Salvage Therapy

If no response to first-line IST in 6 months:

• Alternative donor BMT (unrelated matched donor or haploidentical)
• Eltrombopag alone or in combination
• Alemtuzumab (Campath) – experimental settings
• Enrollment in clinical trials, if available

Monitoring Schedule

Recovery Period of Aplastic Anemia

The recovery period for aplastic anemia varies depending on the severity of the condition, the type of treatment received, and the individual patient’s response. Recovery doesn’t happen overnight—it is a gradual process that can range from several months to over a year.

1. Recovery After Immunosuppressive Therapy (IST)

Medications: Antithymocyte globulin (ATG) + Cyclosporine ± Eltrombopag Timeline:

• Initial response: Within 3 to 6 months
• Full hematologic recovery: Up to 12 months
• Some patients may require maintenance cyclosporine for 1–2 years

Monitoring:

• Weekly CBC during the first 3 months
• Monthly blood tests thereafter
• Liver/kidney function and cyclosporine levels every few weeks

Notes:

• About 60–70% of patients respond to IST
• Some patients may relapse or develop late clonal disorders like PNH or MDS

2. Recovery After Bone Marrow Transplant (BMT)

Best candidates: Young patients with matched sibling donors Timeline:

• Engraftment (initial recovery): 14–28 days post-transplant
• Immune system recovery: 3–6 months for partial, up to 12 months for full immune recovery
• Overall full recovery: Typically 6–12 months, sometimes longer

Monitoring:

• Daily labs during hospital stay (first 30–40 days)
• Weekly to monthly follow-ups for 6–12 months
• Lifelong yearly monitoring for complications or relapse

Notes:

• BMT has a cure rate of up to 90% in ideal conditions
• Graft vs. host disease (GvHD), infections, and organ toxicity are key risks

3. Recovery with Supportive Care Only

For patients not undergoing definitive treatment:

• Symptoms managed with transfusions
• No curative recovery unless spontaneous remission occurs (rare)
• The risk of iron overload, infections, and bleeding remains long-term

Summary Table: Aplastic Anemia Recovery Timeline